Roche, Exelixis' Tecentriq/Cabometyx combo flunks second PhIII
Roche and Exelixis are reporting a second flop out of a trio of Phase III trials designed to test a combination of their PD-L1 drug and tyrosine kinase inhibitor.
Adding Tecentriq, Roche’s blockbuster PD-L1 antibody, to Exelixis’ Cabometyx did not meet the primary endpoint of progression-free survival for a group of patients with kidney cancer who have already received checkpoint therapy, Exelixis wrote in a terse update on the CONTACT-03 study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
